Cardiac peroxiredoxins undergo complex modifications during cardiac oxidant stress

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 295, Issue 1, 2008, Pages

  Schröder, Ewald ^a   Brennan, Jonathan P ^a   Eaton, Philip ^a,b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cysteine; Hydrogen peroxide; Redox signaling

Indexed keywords

HYDROGEN PEROXIDE; PEROXIREDOXIN; PEROXIREDOXIN 1; PEROXIREDOXIN 2; PEROXIREDOXIN 3; PEROXIREDOXIN 5; UNCLASSIFIED DRUG; CYSTEINE; DISULFIDE; OXIDIZING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISULFIDE BOND; GEL PERMEATION CHROMATOGRAPHY; IMMUNOBLOTTING; MALE; MYOFILAMENT; NONHUMAN; OXIDATIVE STRESS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RAT; ANIMAL; DOSE RESPONSE; DRUG EFFECT; ENZYMOLOGY; GEL CHROMATOGRAPHY; HEART MUSCLE; IN VITRO STUDY; METABOLISM; OXIDATION REDUCTION REACTION; PERFUSION; SIGNAL TRANSDUCTION; WISTAR RAT;

ANIMALS; CHROMATOGRAPHY, GEL; CYSTEINE; DISULFIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; HYDROGEN PEROXIDE; IMMUNOBLOTTING; MALE; MYOCARDIUM; OXIDANTS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PERFUSION; PEROXIREDOXINS; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION;

EID: 49849106655     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00017.2008     Document Type: Article

References (44)

1. Araki M, Nanri H, Ejima K, Murasato Y, Fujiwara T, Nakashima Y, Ikeda M. Antioxidant function of the mitochondrial protein SP-22 in the cardiovascular system. J Biol Chem 274: 2271-2278, 1999.
2. Biteau B, Labarre J, Toledano MB. ATP-dependent reduction of cysteine-sulphinic acid by S. cerevisiae sulphiredoxin. Nature 425: 980-984, 2003.
3. Brennan JP, Wait R, Begum S, Bell JR, Dunn MJ, Eaton P. Detection and mapping of widespread intermolecular protein disulfide formation during cardiac oxidative stress using proteomics with diagonal electrophoresis. J Biol Chem 279: 41352-41360, 2004.
4. Brixius K, Schwinger RH, Hoyer F, Napp A, Renner R, Bolck B, Kumin A, Fischer U, Mehlhorn U, Werner S, Bloch W. Isoformspecific downregulation of peroxiredoxin in human failing myocardium. Life Sci 81: 823-831, 2007.
5. Budde H, Flohe L, Hecht HJ, Hofmann B, Stehr M, Wissing J, Lunsdorf H. Kinetics and redox-sensitive oligomerisation reveal negative subunit cooperativity in tryparedoxin peroxidase of Trypanosoma brucei brucei. Biol Chem 384: 619-633, 2003.
6. Cao Z, Roszak AW, Gourlay LJ, Lindsay JG, Isaacs NW. Bovine mitochondrial peroxiredoxin III forms a two-ring catenane. Structure 13: 1661-1664, 2005.
7. Chevallet M, Wagner E, Luche S, van Dorsselaer A, Leize-Wagner E, Rabilloud T. Regeneration of peroxiredoxins during recovery after oxidative stress: only some overoxidized peroxiredoxins can be reduced during recovery after oxidative stress. J Biol Chem 278: 37146-37153, 2003.
8. Choi HJ, Kang SW, Yang CH, Rhee SG, Ryu SE. Crystallization and preliminary X-ray studies of hORF6, a novel human antioxidant enzyme. Acta Crystallogr D 54: 436-437, 1998.
9. Cullingford TE, Wait R, Clerk A, Sugden PH. Effects of oxidative stress on the cardiac myocyte proteome: modifications to peroxiredoxins and small heat shock proteins. J Mol Cell Cardiol 40: 157-172, 2006.
10. Eaton P, Bell RM, Cave AC, Shattock MJ. Ischemic preconditioning: a potential role for protein S-thiolation? Antioxid Redox Signal 7: 882-888, 2005.
11. Evrard C, Capron A, Marchand C, Clippe A, Wattiez R, Soumillion P, Knoops B, Declercq JP. Crystal structure of a dimeric oxidized form of human peroxiredoxin 5. J Mol Biol 337: 1079-1090, 2004.
12. Gourlay LJ, Bhella D, Kelly SM, Price NC, Lindsay JG. Structurefunction analysis of recombinant substrate protein 22 kDa (SP-22). A mitochondrial 2-Cys peroxiredoxin organized as a decameric toroid. J Biol Chem 278: 32631-32637, 2003.
13. Harris JR, Schroder E, Isupov MN, Scheffler D, Kristensen P, Littlechild JA, Vagin AA, Meissner U. Comparison of the decameric structure of peroxiredoxin-II by transmission electron microscopy and X-ray crystallography. Biochim Biophys Acta 1547: 221-234, 2001.
14. Hofmann B, Hecht HJ, Flohe L. Peroxiredoxins. Biol Chem 383: 347-364, 2002.
15. Jang HH, Kim SY, Park SK, Jeon HS, Lee YM, Jung JH, Lee SY, Chae HB, Jung YJ, Lee KO, Lim CO, Chung WS, Bahk JD, Yun DJ, Cho MJ, Lee SY. Phosphorylation and concomitant structural changes in human 2-Cys peroxiredoxin isotype I differentially regulate its peroxidase and molecular chaperone functions. FEBS Lett 580: 351-355, 2006.
16. Jang HH, Lee KO, Chi YH, Jung BG, Park SK, Park JH, Lee JR, Lee SS, Moon JC, Yun JW, Choi YO, Kim WY, Kang JS, Cheong GW, Yun DJ, Rhee SG, Cho MJ, Lee SY. Two enzymes in one: two yeast peroxiredoxins display oxidative stress-dependent switching from a peroxidase to a molecular chaperone function. Cell 117: 625-635, 2004.
17. Jin DY, Chae HZ, Rhee SG, Jeang KT. Regulatory role for a novel human thioredoxin peroxidase in NF-B activation. J Biol Chem 272: 30952-30961, 1997.
18. Kang SW, Rhee SG, Chang TS, Jeong W, Choi MH. 2-Cys peroxiredoxin function in intracellular signal transduction: therapeutic implications. Trends Mol Med 11: 571-578, 2005.
19. Kristensen P, Rasmussen DE, Kristensen BI. Properties of thiol-specific anti-oxidant protein or calpromotin in solution. Biochem Biophys Res Commun 262: 127-131, 1999.
20. Lee TH, Kim SU, Yu SL, Kim SH, Park DS, Moon HB, Dho SH, Kwon KS, Kwon HJ, Han YH, Jeong S, Kang SW, Shin HS, Lee KK, Rhee SG, Yu DY. Peroxiredoxin II is essential for sustaining life span of erythrocytes in mice. Blood 101: 5033-5038, 2003.
21. 83 in PRX1 underscores the structural and functional differences between PRX1 and PRX2. J Biol Chem 282: 22011-22022, 2007.
22. Low FM, Hampton MB, Peskin AV, Winterbourn CC. Peroxiredoxin 2 functions as a noncatalytic scavenger of low-level hydrogen peroxide in the erythrocyte. Blood 109: 2611-2617, 2007.
23. Manevich Y, Feinstein SI, Fisher AB. Activation of the antioxidant enzyme 1-Cys peroxiredoxin requires glutathionylation mediated by heterodimerization with π-GST. Proc Natl Acad Sci USA 101: 3780-3785, 2004.
24. Matsushima S, Ide T, Yamato M, Matsusaka H, Hattori F, Ikeuchi M, Kubota T, Sunagawa K, Hasegawa Y, Kurihara T, Oikawa S, Kinugawa S, Tsutsui H. Overexpression of mitochondrial peroxiredoxin-3 prevents left ventricular remodeling and failure after myocardial infarction in mice. Circulation 113: 1779-1786, 2006.
25. Mayr M, Chung YL, Mayr U, McGregor E, Troy H, Baier G, Leitges M, Dunn MJ, Griffiths JR, Xu Q. Loss of PKC-δ alters cardiac metabolism. Am J Physiol Heart Circ Physiol 287: H937-H945, 2004.
26. Mitsumoto A, Takanezawa Y, Okawa K, Iwamatsu A, Nakagawa Y. Variants of peroxiredoxins expression in response to hydroperoxide stress. Free Radic Biol Med 30: 625-635, 2001.
27. Monteiro G, Horta BB, Pimenta DC, Augusto O, Netto LE. Reduction of 1-Cys peroxiredoxins by ascorbate changes the thiol-specific antioxidant paradigm, revealing another function of vitamin C. Proc Natl Acad Sci USA 104: 4886-4891, 2007.
28. 2-induced cell death. J Biol Chem 280: 28775-28784, 2005.
29. Nagy N, Malik G, Fisher AB, Das DK. Targeted disruption of peroxiredoxin 6 gene renders the heart vulnerable to ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 291: H2636-H2640, 2006.
30. Neumann CA, Krause DS, Carman CV, Das S, Dubey DP, Abraham JL, Bronson RT, Fujiwara Y, Orkin SH, Van Etten RA. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature 424: 561-565, 2003.
31. Nguyen-Nhu NT, Berck J, Clippe A, Duconseille E, Cherif H, Boone C, Van der Eecken V, Bernard A, Banmeyer I, Knoops B. Human peroxiredoxin 5 gene organization, initial characterization of its promoter and identification of alternative forms of mRNA. Biochim Biophys Acta 1769: 472-483, 2007.
32. Parsonage D, Youngblood DS, Sarma GN, Wood ZA, Karplus PA, Poole LB. Analysis of the link between enzymatic activity and oligomeric state in AhpC, a bacterial peroxiredoxin. Biochemistry 44: 10583-10592, 2005.
33. Pawloski JR, Hess DT, Stamler JS. Export by red blood cells of nitric oxide bioactivity. Nature 409: 622-626, 2001.
34. Plishker GA, Chevalier D, Seinsoth L, Moore RB. Calcium-activated potassium transport and high molecular weight forms of calpromotin. J Biol Chem 267: 21839-21843, 1992.
35. Rabilloud T, Heller M, Gasnier F, Luche S, Rey C, Aebersold R, Benahmed M, Louisot P, Lunardi J. Proteomics analysis of cellular response to oxidative stress. Evidence for in vivo overoxidation of peroxiredoxins at their active site. J Biol Chem 277: 19396-19401, 2002.
36. Rhee SG, Kang SW, Chang TS, Jeong W, Kim K. Peroxiredoxin, a novel family of peroxidases. IUBMB Life 52: 35-41, 2001.
37. Schroder E, Eaton P. Hydrogen peroxide as an endogenous mediator and exogenous tool in cardiovascular research: issues and considerations. Curr Opin Pharmacol 8: 153-159, 2008.
38. Schroder E, Littlechild JA, Lebedev AA, Errington N, Vagin AA, Isupov MN. Crystal structure of decameric 2-Cys peroxiredoxin from human erythrocytes at 1.7 A resolution. Structure 8: 605-615, 2000.
39. Schroder E, Willis AC, Ponting CP. Porcine natural-killer- enhancing factor-B: oligomerisation and identification as a calpain substrate in vitro. Biochim Biophys Acta 1383: 279-291, 1998.
40. Shau H, Kim AT, Hedrick CC, Lusis AJ, Tompkins C, Finney R, Leung DW, Paglia DE. Endogenous natural killer enhancing factor-B increases cellular resistance to oxidative stresses. Free Radic Biol Med 22: 497-507, 1997.
41. Wang X, Phelan SA, Petros C, Taylor EF, Ledinski G, Jurgens G, Forsman-Semb K, Paigen B. Peroxiredoxin 6 deficiency and atherosclerosis susceptibility in mice: significance of genetic background for assessing atherosclerosis. Atherosclerosis 177: 61-70, 2004.
42. Woo HA, Kang SW, Kim HK, Yang KS, Chae HZ, Rhee SG. Reversible oxidation of the active site cysteine of peroxiredoxins to cysteine sulfinic acid. Immunoblot detection with antibodies specific for the hyperoxidized cysteine-containing sequence. J Biol Chem 278: 47361-47364, 2003.
43. Wood ZA, Schroder E, Robin Harris J, Poole LB. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci 28: 32-40, 2003.
44. Yang KS, Kang SW, Woo HA, Hwang SC, Chae HZ, Kim K, Rhee SG. Inactivation of human peroxiredoxin I during catalysis as the result of the oxidation of the catalytic site cysteine to cysteine-sulfinic acid. J Biol Chem 277: 38029-38036, 2002.